Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 …
PRESS RELEASES
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Access the Akari CEO Corner here TAMPA, FL and LONDON – January 9, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics to Present at the 2026 Biotech Showcase
In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, …
[Read more...] about Akari Therapeutics to Present at the 2026 Biotech Showcase
